Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Blood
    October 2026
  1. CROMBIE JL, Redd R, Phinney C, Forsyth M, et al
    A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.
    Blood. 2026 Oct 6:blood.2026034588. doi: 10.1182/blood.2026034588.
    >> Share

  2. OLSZEWSKI AJ, Eradat HA, Avigdor A, Horowitz NA, et al
    Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.
    Blood. 2026 Oct 5:blood.2026035116. doi: 10.1182/blood.2026035116.
    >> Share

  3. BORRY R, Vilcot F, Tesson B, Moraly J, et al
    STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma.
    Blood. 2026 Oct 5:blood.2025032902. doi: 10.1182/blood.2025032902.
    >> Share

  4. GROMMES C, Nayak L, Kallam A, Peereboom D, et al
    Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial.
    Blood. 2026 Oct 1:blood.2026034926. doi: 10.1182/blood.2026034926.
    >> Share

  5. AHMED S, Martin Garcia-Sancho A, Reguera Ortega JL, Cartron G, et al
    Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.
    Blood. 2026;148:1789-1799.
    >> Share

  6. WANG C, Geng X, Abdelrahman S, Fu Y, et al
    A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.
    Blood. 2026;148:1816-1832.
    >> Share

    September 2026
  7. ABRAMSON JS, Siddiqi T, Gordon LI, Lunning M, et al
    Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.
    Blood. 2026;148:1388-1393.
    >> Share

  8. PATEL K, Shah GL, Schoder H, Ganesan N, et al
    Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial.
    Blood. 2026 Sep 8:blood.2026035115. doi: 10.1182/blood.2026035115.
    >> Share

  9. KRUPKA JA, Pott C, Hodson DJ
    Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL).
    Blood. 2026 Sep 3:blood.2026033074. doi: 10.1182/blood.2026033074.
    >> Share

  10. NITHAGON P, Saksena A
    Classic Hodgkin lymphoma showing interfollicular and intrasinusoidal involvement.
    Blood. 2026;148:1364.
    >> Share

  11. MAGNANO L, Lopez-Guillermo A, Maurer MJ
    A framework to challenge the dogma of incurability in follicular lymphoma.
    Blood. 2026 Sep 2:blood.2026035096. doi: 10.1182/blood.2026035096.
    >> Share

    August 2026

  12. Casulo C, Dixon JG, Le-Rademacher J, et al; FLASH (Follicular Lymphoma Analysis of Surrogacy Hypothesis) Group. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(1
    Blood. 2026;148:1067.
    >> Share

  13. REJESKI K, Banerjee R, Hill JA
    How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.
    Blood. 2026;148:927-938.
    >> Share


  14. Abro B, Maurer MJ, Habermann TM, et al. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis. Blood. 2024;144(19):2063-2066.
    Blood. 2026;148:914.
    >> Share

  15. MARTIN P
    How soon is now for new treatments for mantle cell lymphoma?
    Blood. 2026;148:641-642.
    >> Share

  16. ALLBEE AW, Sadigh S
    Disseminated cryptococcal lymphadenitis mimicking lymphoma and masked by prozone effect.
    Blood. 2026;148:794.
    >> Share


  17. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma, Blood. 2008;111(4):2230-2237.
    Blood. 2026;148:795.
    >> Share

  18. BUDDE LE, Kamdar M, Assouline SE, Chavez JC, et al
    Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
    Blood. 2026;148:682-692.
    >> Share

    July 2026

  19. Domostegui A, Peddigari S, Mercer CA, et al. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood. 2021;137(24):3351-3364.
    Blood. 2026;148:640.
    >> Share

  20. POGGIO T, Grassel L, Andrieux G, Gomez Martinez AM, et al
    CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma.
    Blood. 2026 Jul 28:blood.2026033240. doi: 10.1182/blood.2026033240.
    >> Share

  21. ARAUJO-AYALA F, Ros M, Alexandru R, Mateos-Jaimez J, et al
    CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.
    Blood. 2026 Jul 22:blood.2025032663. doi: 10.1182/blood.2025032663.
    >> Share


  22. Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood. 2021;138(9):785-789.
    Blood. 2026;148:389.
    >> Share

  23. CHIHARA D, Westin JR
    The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.
    Blood. 2026 Jul 6:blood.2026034393. doi: 10.1182/blood.2026034393.
    >> Share

  24. WANG M, Hoffmann MS, Wrobel T, Trneny M, et al
    First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients >/=65 years or with TP53 mutations.
    Blood. 2026 Jul 1:blood.2025032833. doi: 10.1182/blood.2025032833.
    >> Share

    June 2026
  25. FALCONER J
    The RELEVANCE of long-term follow-up in follicular lymphoma.
    Blood. 2026;147:2993-2994.
    >> Share

  26. SPECHT L
    Less is more in primary cutaneous indolent B-cell lymphoma.
    Blood. 2026;147:2992-2993.
    >> Share


  27. Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.
    Blood. 2026;147:3123.
    >> Share

  28. KIM WS, Kim SJ, Yoon DH, Cho H, et al
    Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).
    Blood. 2026 Jun 12:blood.2025032636. doi: 10.1182/blood.2025032636.
    >> Share


  29. Grabow S, Delbridge ARD, Valente LJ, Strasser A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood. 2014;124(26):3939-3946.
    Blood. 2026;147:2988.
    >> Share

  30. YU C, Holloman M, Kim A, Chang Y, et al
    Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.
    Blood. 2026;147:2713-2727.
    >> Share

    May 2026
  31. GOBEL C, Niccolai R, Gregoricchio S, de Groot MHP, et al
    DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma.
    Blood. 2026 May 29:blood.2025031615. doi: 10.1182/blood.2025031615.
    >> Share

  32. HU S, Qin Y, Yi HM, Huang YH, et al
    N6-methyladenosine reader IGF2BP2 in T-cell lymphoma.
    Blood. 2026 May 21:blood.2026034186. doi: 10.1182/blood.2026034186.
    >> Share

  33. LOSSOS IS
    MRD testing in Hodgkin lymphoma: filling the knowledge gaps.
    Blood. 2026;147:2159-2160.
    >> Share

  34. AHMED AA, Tadros S
    Classic Hodgkin lymphoma with IGH::CCND1 rearrangement: evidence of clonal relation to preceding mantle cell lymphoma.
    Blood. 2026;147:2278.
    >> Share

  35. VANNUCCHI AM, Patel JL, Kiladjian JJ
    Myeloid/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.
    Blood. 2026;147:2171-2175.
    >> Share

  36. HEGER JM, Mattlener J, Kaul H, Ferdinandus J, et al
    MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.
    Blood. 2026;147:2194-2202.
    >> Share

  37. DAVIDSON-SWINTON HR, Iyer S, Kolchinski A, Salem JA, et al
    Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.
    Blood. 2026;147:2226-2237.
    >> Share

    April 2026
  38. TOBIN JWD, Gandhi MK
    SIGN of the times: DC-SIGN and the follicular lymphoma niche.
    Blood. 2026;147:2025-2026.
    >> Share


  39. Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137(23):3272-3276.
    Blood. 2026;147:2157.
    >> Share

  40. BARIBOLOKA KT, Serrano-Saenz S, Savcigil DP, Spoeck S, et al
    Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.
    Blood. 2026 Apr 23:blood.2026033320. doi: 10.1182/blood.2026033320.
    >> Share

  41. SCHORB E
    Mapping risk and therapy in secondary CNS lymphoma.
    Blood. 2026;147:1783-1784.
    >> Share

  42. STEVENSON FK, Stamatopoulos K
    The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.
    Blood. 2026;147:1793-1803.
    >> Share

  43. VODICKA P, El-Galaly TC, Prochazka V, Flowers CR, et al
    Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.
    Blood. 2026 Apr 14:blood.2026033090. doi: 10.1182/blood.2026033090.
    >> Share

  44. AOKI T, Kuruvilla J
    Targeted therapy in early-stage classical Hodgkin lymphoma.
    Blood. 2026;147:1655-1657.
    >> Share

  45. SCHROERS-MARTIN JG
    Digging deep for the roots of lymphoma.
    Blood. 2026;147:1657-1658.
    >> Share

  46. ROBERTZ AS, Buhnen I, Meissner J, Trautmann-Grill K, et al
    Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.
    Blood. 2026 Apr 2:blood.2025031809. doi: 10.1182/blood.2025031809.
    >> Share

    March 2026
  47. GOWER N, Feugier P, Westin JR, Schiano de Colella JS, et al
    Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
    Blood. 2026 Mar 31:blood.2026033126. doi: 10.1182/blood.2026033126.
    >> Share


  48. Ronceray L, Huibers MHW, Reutter K, et al. High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition. Blood. 2026;147(2):209-214.
    Blood. 2026;147:1504.
    >> Share


  49. Jaye DL, Feldman AL. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma. Blood. 2023;141(17):2160.
    Blood. 2026;147:1504.
    >> Share

  50. KAMDAR M, Bartlett NL
    From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma.
    Blood. 2026 Mar 23:blood.2025030859. doi: 10.1182/blood.2025030859.
    >> Share


  51. HOD08 for low-risk pediatric Hodgkin lymphoma.
    Blood. 2026;147:1381.
    >> Share

  52. KAULEN LD, Nayak L, Karschnia P, Kraai I, et al
    Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.
    Blood. 2026 Mar 17:blood.2025031869. doi: 10.1182/blood.2025031869.
    >> Share

  53. OERTEL M, Dabaja BS, Gorlich D, Thomas BR, et al
    Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.
    Blood. 2026 Mar 13:blood.2025032050. doi: 10.1182/blood.2025032050.
    >> Share

  54. FELDMAN AL, Dasari S, Rimsza LM, Scott DW, et al
    Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.
    Blood. 2026;147:1199-1214.
    >> Share

  55. ZAMMAR G, Cheah CY
    Pretransplant promise for PD-1 in Hodgkin lymphoma.
    Blood. 2026;147:1015-1017.
    >> Share

  56. RHEIN S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, et al
    A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.
    Blood. 2026;147:1058-1069.
    >> Share

  57. CROMBIE JL, Ahmed S, Frigault MJ, Hunter BD, et al
    Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
    Blood. 2026 Mar 3:blood.2025031733. doi: 10.1182/blood.2025031733.
    >> Share

    February 2026
  58. LI X, Liu M, Shi Q, Du ZS, et al
    CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.
    Blood. 2026 Feb 27:blood.2025031156. doi: 10.1182/blood.2025031156.
    >> Share

  59. MARCOUX P, Gava F, Tosolini M, Gravelle P, et al
    Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL.
    Blood. 2026 Feb 26:blood.2025031309. doi: 10.1182/blood.2025031309.
    >> Share

  60. STEWART J, Damania B
    Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.
    Blood. 2026;147:848-862.
    >> Share

  61. DOWLING MR, Cliff ERS, Jeffrey A, Cashion C, et al
    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.
    Blood. 2026 Feb 17:blood.2025032307. doi: 10.1182/blood.2025032307.
    >> Share

  62. YENWONGFAI LN, Francischetti IMB
    Follicular lymphoma transformed to classic Hodgkin lymphoma.
    Blood. 2026;147:800.
    >> Share

  63. SORIAL MN, Malpica Castillo LE, Chiattone C, Julia E, et al
    Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.
    Blood. 2026;147:755-767.
    >> Share

  64. DIEFENBACH C, Jegede O, Wang V, Ansell SM, et al
    A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.
    Blood. 2026 Feb 9:blood.2025029546. doi: 10.1182/blood.2025029546.
    >> Share

  65. DORANDO HK, Andrews JM, Khatavkar OU, Borcherding N, et al
    Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance.
    Blood. 2026 Feb 9:blood.2025029012. doi: 10.1182/blood.2025029012.
    >> Share


  66. Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term stud
    Blood. 2026;147:703.
    >> Share

    January 2026
  67. URANO Y, Satou A
    Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.
    Blood. 2026;147:602.
    >> Share

  68. CHIODIN G, Tatterton DJ, Rock PJ, Del Rio L, et al
    DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.
    Blood. 2026 Jan 20:blood.2025030049. doi: 10.1182/blood.2025030049.
    >> Share

  69. THOMPSON C, Trneny M, Morschhauser F, Salles G, et al
    PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
    Blood. 2026;147:254-265.
    >> Share

  70. FLERLAGE JE, Feraco AM MD, MMSc, Zhou Y, Zheng Y MS, et al
    Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.
    Blood. 2026 Jan 13:blood.2025029535. doi: 10.1182/blood.2025029535.
    >> Share

  71. ARMAND P
    Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.
    Blood. 2026;147:95.
    >> Share

  72. LAURENT C, Bertoni F
    The biology of marginal zone lymphoma subtypes: challenge and relevance of classification.
    Blood. 2026;147:105-114.
    >> Share

  73. ALDERUCCIO JP, Baggio D, Han S, Ghione P, et al
    Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.
    Blood. 2026 Jan 5:blood.2025031455. doi: 10.1182/blood.2025031455.
    >> Share

  74. WIEGAND L, Silva P, Noerenberg D, Christen F, et al
    Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.
    Blood. 2026 Jan 5:blood.2025030489. doi: 10.1182/blood.2025030489.
    >> Share

    December 2025
  75. ABRAMSON JS, Straus DJ, Bartlett NL, Burke JM, et al
    Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.
    Blood. 2025 Dec 29:blood.2025030190. doi: 10.1182/blood.2025030190.
    >> Share

  76. LUAN D, Valid OB, Beyar-Katz O, Tix T, et al
    Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.
    Blood. 2025 Dec 23:blood.2025031476. doi: 10.1182/blood.2025031476.
    >> Share

  77. STALLS JS, Park DC
    Leukemic phase of hepatosplenic T-cell lymphoma.
    Blood. 2025;146:3129.
    >> Share

  78. DESAI SH, Moskowitz AJ, Merryman RW, Shah HR, et al
    PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.
    Blood. 2025 Dec 17:blood.2025030151. doi: 10.1182/blood.2025030151.
    >> Share

    November 2025

  79. Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.
    Blood. 2025;146:2729.
    >> Share

  80. HOSOYA H, Bastidas Torres AN, Fernandez-Pol S, Gubatan JM, et al
    Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.
    Blood. 2025 Nov 25:blood.2025031423. doi: 10.1182/blood.2025031423.
    >> Share

  81. TAYLOR J
    Big cells, bigger BTK resistance in mantle cell lymphoma.
    Blood. 2025;146:2500-2501.
    >> Share

  82. HU S, Tang G
    Mantle cell lymphoma with KMT2A rearrangement.
    Blood. 2025;146:2491.
    >> Share

  83. FOURNIER B, Latour S
    Methylation profiling: unmasking CAEBV's lymphoma connection.
    Blood. 2025;146:2279-2280.
    >> Share

  84. ELSHARAWI I, Selegean S
    Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.
    Blood. 2025;146:2370.
    >> Share

  85. JAWOREK CP, Brockelmann PJ
    Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?
    Blood. 2025 Nov 1:blood.2025029935. doi: 10.1182/blood.2025029935.
    >> Share

    October 2025
  86. SHANMUGAM M
    Starving lymphoma with alpha-KG supplementation.
    Blood. 2025;146:2151-2153.
    >> Share

  87. PANDIRI M, Arber DA
    Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma.
    Blood. 2025;146:2272.
    >> Share

  88. RONCERAY L, Huibers MHW, Reutter K, Abla O, et al
    High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.
    Blood. 2025 Oct 29:blood.2025031086. doi: 10.1182/blood.2025031086.
    >> Share

  89. VAN MEERTEN T, Kersten MJ, Iacoboni G, Hess GR, et al
    Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.
    Blood. 2025 Oct 29:blood.2025029734. doi: 10.1182/blood.2025029734.
    >> Share

  90. VARDHANA SA
    Smarter combos, stronger T cells in lymphoma.
    Blood. 2025;146:1742-1744.
    >> Share

  91. ARMAND P
    Introduction to a review series on follicular lymphoma: solved or insoluble problem?
    Blood. 2025;146:1739-1740.
    >> Share

  92. SHI M, Rech KL
    T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma.
    Blood. 2025;146:1868.
    >> Share

    September 2025
  93. ZUCCA E, Ceriani L, Ciccone G, Di Rocco A, et al
    Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
    Blood. 2025 Sep 12:blood.2025028823. doi: 10.1182/blood.2025028823.
    >> Share


  94. Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025;145(20):2303-2311.
    Blood. 2025;146:1374.
    >> Share

  95. FALCHI L, Sureda A, Leppa S, Vermaat JS, et al
    Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.
    Blood. 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909.
    >> Share

  96. HAVRANEK O
    Classic Hodgkin lymphoma: the journey over the destination.
    Blood. 2025;146:1152-1153.
    >> Share

  97. TATTERTON DJ, Newby ML, Allen JD, Sale BJ, et al
    The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma.
    Blood. 2025 Sep 2:blood.2025029163. doi: 10.1182/blood.2025029163.
    >> Share

  98. PAL I, Illendula A, Joyner AM, Manavalan JS, et al
    Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma.
    Blood. 2025 Sep 2:blood.2024027997. doi: 10.1182/blood.2024027997.
    >> Share

    August 2025
  99. SCHERER F
    Cracking the POD24 code in follicular lymphoma.
    Blood. 2025;146:899-900.
    >> Share


  100. Allo-HCT in Hodgkin lymphoma after CPI.
    Blood. 2025;146:1030.
    >> Share

  101. XU P, Zhu Y, Shi ZY, Wang L, et al
    A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.
    Blood. 2025 Aug 19:blood.2025028649. doi: 10.1182/blood.2025028649.
    >> Share

  102. CASULO C, Sehn LH
    Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
    Blood. 2025 Aug 14:blood.2024026018. doi: 10.1182/blood.2024026018.
    >> Share

  103. QIU L, Thakral B
    Intrasinusoidal pleomorphic mantle cell lymphoma mimicking intravascular large B-cell lymphoma.
    Blood. 2025;146:897.
    >> Share

  104. REJESKI K, Sanz J, Fei T, Nair MS, et al
    T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
    Blood. 2025;146:834-846.
    >> Share

  105. SAM J, Leclercq-Cohen G, Gebhardt S, Surowka M, et al
    Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
    Blood. 2025 Aug 1:blood.2025028863. doi: 10.1182/blood.2025028863.
    >> Share

    July 2025
  106. JAAFAR C, Ethiraj P, Qiu Z, Lin AP, et al
    alpha-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development.
    Blood. 2025 Jul 23:blood.2024028069. doi: 10.1182/blood.2024028069.
    >> Share

  107. WANG W, Cai Q, Liu Y, Nie L, et al
    TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.
    Blood. 2025 Jul 23:blood.2024026919. doi: 10.1182/blood.2024026919.
    >> Share

  108. KITTAI AS, Marchetti M, Al-Sawaf O, Benjamini O, et al
    International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
    Blood. 2025;146:291-303.
    >> Share

  109. ALDERUCCIO JP, Noy A
    The Treatment of Marginal Zone Lymphoma.
    Blood. 2025 Jul 15:blood.2024028269. doi: 10.1182/blood.2024028269.
    >> Share

  110. BROOKS TR, Zabor EC, Bedelu Y, Yang X MD, et al
    Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
    Blood. 2025 Jul 15:blood.2025029117. doi: 10.1182/blood.2025029117.
    >> Share

  111. SCARISBRICK JJ, Quaglino P, Whittaker SJ, Bagot M, et al
    A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification.
    Blood. 2025 Jul 15:blood.2025029628. doi: 10.1182/blood.2025029628.
    >> Share

  112. KAULEN LD, Martinez-Lage M, Abramson JS, Karschnia P, et al
    Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy.
    Blood. 2025 Jul 15:blood.2025028964. doi: 10.1182/blood.2025028964.
    >> Share

  113. AL JABRI M, Sakhdari A
    A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22alt case.
    Blood. 2025;146:260.
    >> Share

  114. YANG H, Zhang W, Ravanmehr V, Cui G, et al
    Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement.
    Blood. 2025;146:191-205.
    >> Share

  115. PERALES MA, Awan FT, Boumendil A, Patel J, et al
    Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis.
    Blood. 2025 Jul 7:blood.2024027197. doi: 10.1182/blood.2024027197.
    >> Share

    June 2025
  116. RAI S, Duns G, Frontzek F, Wong JCH, et al
    Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma.
    Blood. 2025 Jun 20:blood.2025028412. doi: 10.1182/blood.2025028412.
    >> Share

  117. FREEMAN CL, Srinivasan S, Hodkinson B, Deshpande S, et al
    Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status.
    Blood. 2025;145:3052-3056.
    >> Share

  118. MULLER F, Schwingen NR, Hagen M, Scholz JK, et al
    Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.
    Blood. 2025 Jun 12:blood.2025028375. doi: 10.1182/blood.2025028375.
    >> Share

  119. SELVARAJAH S, Xia D
    A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
    Blood. 2025;145:2931.
    >> Share

  120. CLAUDEL A, Cottereau AS, Bachy E, Itti E, et al
    Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
    Blood. 2025 Jun 11:blood.2024027727. doi: 10.1182/blood.2024027727.
    >> Share

  121. HAWKES EA, Gregory GP
    Burkitt lymphoma: click here to add to CAR-T?
    Blood. 2025;145:2678-2680.
    >> Share

  122. TOOZE R, Klein U
    Exploiting tumor-derived IL-10 activity in lymphoma therapy.
    Blood. 2025;145:2676-2678.
    >> Share

  123. KITAGAWA Y, Jaffe ES
    Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease.
    Blood. 2025;145:2799.
    >> Share

    May 2025
  124. SHAH B, Nejati R
    Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma.
    Blood. 2025;145:2671.
    >> Share

  125. REED HD, Do H, Weller E, Harris MH, et al
    Lymphoid malignancies in patients with Shwachman-Diamond syndrome.
    Blood. 2025;145:2528-2532.
    >> Share

  126. TUMULURU S, Godfrey JK, Cooper A, Yu J, et al
    Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
    Blood. 2025;145:2460-2472.
    >> Share

  127. YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
    A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
    Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
    >> Share

  128. PARRY EM, Okosun J
    An Updated Understanding of Follicular Lymphoma Transformation.
    Blood. 2025 May 15:blood.2024026016. doi: 10.1182/blood.2024026016.
    >> Share

  129. WANG X, Yi H
    Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
    Blood. 2025;145:2396.
    >> Share

  130. PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
    Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
    Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
    >> Share

  131. PIROSA MC, Bruscaggin A, Terzi di Bergamo L, Salehi M, et al
    A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA.
    Blood. 2025 May 13:blood.2024027355. doi: 10.1182/blood.2024027355.
    >> Share


  132. Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025;145(3):290-299.
    Blood. 2025;145:2231.
    >> Share

  133. DU MQ
    EMZL at various sites: learning from each other.
    Blood. 2025;145:2117-2127.
    >> Share

  134. PARISI X, Medeiros LJ
    When lymphoma mimics adenocarcinoma: signet ring morphology in follicular lymphoma.
    Blood. 2025;145:2104.
    >> Share

  135. CHAPUY B, Wood T, Stewart C, Dunford A, et al
    DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.
    Blood. 2025;145:2041-2055.
    >> Share

    April 2025
  136. MARCO-AYALA J, Ortuno FJ
    Appearances deceive: unmasking mantle cell lymphoma with prolymphocytic morphology.
    Blood. 2025;145:1701.
    >> Share

  137. BRODY JD, Jorgensen J, Belada D, Costello R, et al
    Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
    Blood. 2025;145:1621-1631.
    >> Share

  138. STEIDL C
    The immunotherapy real estate of Hodgkin lymphoma.
    Blood. 2025;145:1445-1447.
    >> Share

  139. GOTTSCHLICH A, Grunmeier R, Hoffmann GV, Nandi S, et al
    Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.
    Blood. 2025;145:1536-1552.
    >> Share

  140. TOPP MS, Matasar M, Allan JN, Ansell SM, et al
    Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
    Blood. 2025;145:1498-1509.
    >> Share

    March 2025
  141. BAKHSHI TJ, Pina-Oviedo S
    Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2025;145:1437.
    >> Share

  142. ARAUJO-AYALA F, Beguelin W
    Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.
    Blood. 2025 Mar 16:blood.2024026020. doi: 10.1182/blood.2024026020.
    >> Share

  143. KIM SJ, Lim JQ, Yoon SE, Yang DH, et al
    Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma.
    Blood. 2025 Mar 12:blood.2024027109. doi: 10.1182/blood.2024027109.
    >> Share

  144. PRATS-MARTIN C, Morales-Camacho RM
    Prolymphocytic progression of splenic marginal zone lymphoma.
    Blood. 2025;145:1097.
    >> Share

  145. GONZALEZ MANCERA M, Silva O
    ALK+ anaplastic large cell lymphoma expressing CD33 and myeloid nuclear differentiation antigen.
    Blood. 2025;145:1098.
    >> Share

  146. LI W, Wang R, Wang J, Chai D, et al
    Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.
    Blood. 2025;145:1047-1060.
    >> Share

    February 2025
  147. DI M, Maurer MJ, Flowers CR
    End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
    Blood. 2025 Feb 28:blood.2024026978. doi: 10.1182/blood.2024026978.
    >> Share

  148. MULVEY E, Rutherford SC, Leonard JP
    The Future of Follicular Lymphoma Management: Strategies on the Horizon.
    Blood. 2025 Feb 28:blood.2024026017. doi: 10.1182/blood.2024026017.
    >> Share

  149. NGUYEN VTM, Namba H, Porter H, Shlyueva D, et al
    Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma.
    Blood. 2025 Feb 26:blood.2024026534. doi: 10.1182/blood.2024026534.
    >> Share

  150. AL JABRI M, Chang H
    Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
    Blood. 2025;145:897.
    >> Share

  151. ARMAND P
    Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness.
    Blood. 2025;145:653-654.
    >> Share

  152. JAIN P, Wang M
    High-risk MCL: recognition and treatment.
    Blood. 2025;145:683-695.
    >> Share

  153. SILKENSTEDT E, Dreyling M
    Treatment of relapsed/refractory MCL.
    Blood. 2025;145:673-682.
    >> Share

  154. SARKOZY C, Tessoulin B, Chiron D
    Unraveling MCL biology to understand resistance and identify vulnerabilities.
    Blood. 2025;145:696-707.
    >> Share

  155. LEWIS CS, Barraclough A, Hawkes EA
    Emerging biomarkers for CD3xCD20 bispecific antibodies in lymphoma.
    Blood. 2025 Feb 12:blood.2024025772. doi: 10.1182/blood.2024025772.
    >> Share

  156. CHAVEZ JC, Dickinson M, Munoz J, Ulrickson ML, et al
    Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12).
    Blood. 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347.
    >> Share

  157. SAMPLES L, Sadrzadeh H, Frigault MJ, Jacobson CA, et al
    Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
    Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831.
    >> Share

  158. KADY N, Abdelrahman S, Rauf AM, Burgess A, et al
    The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas.
    Blood. 2025;145:597-611.
    >> Share

  159. GARCIA-LACARTE M, Grijalba SC, Melchor Sanchez J, Pascual M, et al
    IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.
    Blood. 2025 Feb 3:blood.2024025755. doi: 10.1182/blood.2024025755.
    >> Share

    January 2025
  160. BACHY E, Linton K
    Frontline treatment of follicular lymphoma: What will it take to change current practice?
    Blood. 2025 Jan 27:blood.2024026019. doi: 10.1182/blood.2024026019.
    >> Share

  161. WANG WJ, Hu Z
    CD5-positive high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements.
    Blood. 2025;145:455.
    >> Share

  162. CABALLERO GONZALEZ AC, Ujaldon-Miro C, Pujol-Fernandez P, Montserrat-Torres R, et al
    HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
    Blood. 2025 Jan 22:blood.2024026758. doi: 10.1182/blood.2024026758.
    >> Share

  163. ZHOU T, Elenitoba-Johnson KSJ
    HLA-I aberrations in cutaneous T-cell lymphoma.
    Blood. 2025;145:252-253.
    >> Share

  164. YU W, Li P, Zhou L, Yang M, et al
    A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Blood. 2025 Jan 15:blood.2024026401. doi: 10.1182/blood.2024026401.
    >> Share

  165. GOBEL C, Niccolai R, de Groot MHP, Jayachandran J, et al
    Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B-cell Lymphoma.
    Blood. 2025 Jan 10:blood.2024025500. doi: 10.1182/blood.2024025500.
    >> Share

  166. BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
    Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
    Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
    >> Share

    December 2024
  167. NAHARRO EF, Linden MA
    Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
    Blood. 2024;144:2793.
    >> Share

  168. YENWONGFAI LN, Francischetti IMB
    Prominent expansion of EBV+ large B cells obscuring follicular helper T-cell lymphoma.
    Blood. 2024;144:2682.
    >> Share

  169. SEHN LH, Hallek M
    Introduction to a review series on high-risk aggressive lymphoma.
    Blood. 2024;144:2561-2562.
    >> Share

  170. DAVIES AJ
    The high-grade B-cell lymphomas: double hit and more.
    Blood. 2024;144:2583-2592.
    >> Share

  171. ROSCHEWSKI M, Phelan JD, Jaffe ES
    Primary large B-cell lymphomas of immune-privileged sites.
    Blood. 2024;144:2593-2603.
    >> Share

  172. DABROWSKA-IWANICKA A, Nowakowski GS
    DLBCL: who is high risk and how should treatment be optimized?
    Blood. 2024;144:2573-2582.
    >> Share


  173. Flavell JR, Baumforth KRN, Wood VHJ, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus-encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood. 2008;111(1):292-301.
    Blood. 2024;144:2559.
    >> Share

  174. LEE HJ, Ramchandren R, Friedman J, Melear JM, et al
    Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
    Blood. 2024 Dec 2:blood.2024024681. doi: 10.1182/blood.2024024681.
    >> Share

    November 2024
  175. IACOBONI G, Morschhauser F
    Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies.
    Blood. 2024 Nov 14:blood.2024025699. doi: 10.1182/blood.2024025699.
    >> Share

  176. CHEVALIER S, Legrand C
    B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
    Blood. 2024;144:2067.
    >> Share

    October 2024
  177. IQBAL J, Inghirami G, Chan WC
    New insights into the biology of T-cell lymphomas.
    Blood. 2024;144:1873-1886.
    >> Share

  178. DE LEVAL L, Gaulard P, Dogan A
    A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.
    Blood. 2024;144:1855-1872.
    >> Share

  179. MARCHI E, Craig JW, Kalac M
    Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL).
    Blood. 2024;144:1898-1909.
    >> Share

  180. MOSKOWITZ AJ, Stuver RN, Horwitz SM
    Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).
    Blood. 2024;144:1887-1897.
    >> Share

  181. SEHN LH, Bartlett NL, Matasar MJ, Schuster SJ, et al
    Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >/=2 prior therapies.
    Blood. 2024 Oct 24:blood.2024025454. doi: 10.1182/blood.2024025454.
    >> Share

  182. ALDUAIJ W, Jiang A, Villa D, Collinge BJ, et al
    CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL.
    Blood. 2024 Oct 23:blood.2024025725. doi: 10.1182/blood.2024025725.
    >> Share

  183. KUMAR A, Soumerai JD, Abramson JS, Barnes JA, et al
    Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.
    Blood. 2024 Oct 22:blood.2024025563. doi: 10.1182/blood.2024025563.
    >> Share

  184. HU J, Dunbar CE
    T-Cell Lymphomas in Recipients of CAR-T Cells: Assessing Risks and Causalities.
    Blood. 2024 Oct 11:blood.2024025828. doi: 10.1182/blood.2024025828.
    >> Share

  185. KWANG AC, Duran GE, Fernandez-Pol S, Najidh S, et al
    Genetic alteration of class I HLA in cutaneous T-cell lymphoma.
    Blood. 2024 Oct 10:blood.2024024817. doi: 10.1182/blood.2024024817.
    >> Share

  186. ALIG SK
    FISHing for clarity in double-hit lymphomas.
    Blood. 2024;144:1550-1552.
    >> Share


  187. Friedberg JW, Bordoni R, Patel-Donnelly D, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143(9):786-795.
    Blood. 2024;144:1647.
    >> Share

  188. COLLINGE B, Ben-Neriah S, Hilton LK, Alduaij W, et al
    Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2.
    Blood. 2024;144:1611-1616.
    >> Share

  189. LAURENT C, Trisal P, Tesson B, Seth S, et al
    Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance.
    Blood. 2024 Oct 7:blood.2024024496. doi: 10.1182/blood.2024024496.
    >> Share

  190. WALLACE DS, Loh KP, Casulo C
    How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Blood. 2024 Oct 2:blood.2024024788. doi: 10.1182/blood.2024024788.
    >> Share

    September 2024
  191. POCOCK R, Mansour MR
    T-ALL and T-LBL: a notch apart.
    Blood. 2024;144:1356-1357.
    >> Share

  192. TABATA R, Matsue K
    ALK-positive anaplastic large cell lymphoma, Hodgkin-like pattern with unexplained fever.
    Blood. 2024;144:1460.
    >> Share

  193. QUALLS DA, Armand P, Salles GA
    The current landscape of frontline large B-cell lymphoma trials.
    Blood. 2024 Sep 24:blood.2023023789. doi: 10.1182/blood.2023023789.
    >> Share


  194. Laurent C, Dietrich S, Tarte K. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2024;143(12):1080-1090.
    Blood. 2024;144:1349.
    >> Share


  195. Hill LC, Rouce RH, Wu MJ, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024;143(13):1231-1241.
    Blood. 2024;144:1349.
    >> Share

  196. ABRO B, Maurer MJ, Habermann TM, Burack R, et al
    Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis.
    Blood. 2024 Sep 10:blood.2024025681. doi: 10.1182/blood.2024025681.
    >> Share

  197. MAURER K, Grabski IN, Houot R, Gohil SH, et al
    Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma.
    Blood. 2024 Sep 6:blood.2024024381. doi: 10.1182/blood.2024024381.
    >> Share

    August 2024
  198. ZHOU Q, Chang H
    Circulating composite B- and T-cell lymphoma.
    Blood. 2024;144:1027.
    >> Share

  199. WALLACE DS, Barr PM
    Ready, AIM, stop: ibrutinib plus venetoclax in MCL.
    Blood. 2024;144:800-802.
    >> Share

  200. BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
    Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
    Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
    >> Share

  201. PABST T, Bacher U
    Boosting CAR T cells against lymphomas.
    Blood. 2024;144:689-691.
    >> Share

  202. CHANG CA, Emberley E, D'Souza AL, Zhao W, et al
    ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
    Blood. 2024;144:757-770.
    >> Share

  203. WANG T, Silva O
    HHV-8+ diffuse large B-cell lymphoma with EBV coinfection occurring posttransplant.
    Blood. 2024;144:677.
    >> Share

  204. NIE J, Wang C, Zheng L, Liu Y, et al
    Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma.
    Blood. 2024 Aug 2:blood.2024024487. doi: 10.1182/blood.2024024487.
    >> Share

  205. KUPPERS R
    MYC translocation architecture in B-NHL.
    Blood. 2024;144:469-471.
    >> Share

  206. ARAFAT S, Don M
    A case of Richter transformation to diffuse large B-cell lymphoma with aberrant T-cell marker expression.
    Blood. 2024;144:586.
    >> Share

    July 2024
  207. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
    Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
    Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
    >> Share

  208. RYAN CE, Cohen JB
    Is rituximab retro in mantle cell lymphoma?
    Blood. 2024;144:241-243.
    >> Share

  209. NABEEL H, Bhagat G
    Double-hit, double-expressor follicular lymphoma with plasmacytic differentiation.
    Blood. 2024;144:339.
    >> Share


  210. Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142(10):878-886.
    Blood. 2024;144:341.
    >> Share

  211. PICCALUGA PP
    SOX11 in EBV-negative Burkitt lymphoma.
    Blood. 2024;144:128-129.
    >> Share

  212. FALINI B, Lazzi S
    Mantle cell lymphoma with IRTA1+ reactive expansion of the marginal zone.
    Blood. 2024;144:237.
    >> Share

    June 2024
  213. LUCENA LAGE S, Ramaswami R, Rocco J, Rupert A, et al
    Inflammasome activation in patients with Kaposi sarcoma herpesvirus (KSHV)-associated disorders.
    Blood. 2024 Jun 28:blood.2024024144. doi: 10.1182/blood.2024024144.
    >> Share

  214. BIDOT S, Feldman AL
    Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2024;143:2808.
    >> Share

  215. FLAIFEL A, Rocco JM
    HHV-6 lymphadenitis with DRESS syndrome: another lymphoma mimic.
    Blood. 2024;143:2671.
    >> Share

  216. CHRISMAN LP, Trimark PF, Pang Y, Pease DR, et al
    Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify Sezary syndrome patients with low blood burden.
    Blood. 2024 Jun 7:blood.2023023584. doi: 10.1182/blood.2023023584.
    >> Share

    May 2024
  217. SMITH MR, Jegede O, Martin P, Till B, et al
    Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
    Blood. 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962.
    >> Share

  218. APAYDIN ARIKAN E, Jaffe ES
    Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces.
    Blood. 2024;143:2337.
    >> Share

  219. BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
    CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
    Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
    >> Share

  220. JAIN P, Jelloul FZ
    Biclonal mantle cell lymphoma.
    Blood. 2024;143:2217.
    >> Share

  221. GUPTA M, Bradley J, Massaad E, Burns E, et al
    Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma.
    Blood. 2024 May 22:blood.2024023832. doi: 10.1182/blood.2024023832.
    >> Share

  222. MALINVERNI C, Bernardelli A, Glimelius I, Mirandola M, et al
    Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
    Blood. 2024 May 16:blood.2023023525. doi: 10.1182/blood.2023023525.
    >> Share


  223. MRD and EFS in pediatric T-lymphoblastic lymphoma.
    Blood. 2024;143:2111.
    >> Share


  224. Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
    Blood. 2024;143:2108-2110.
    >> Share

  225. YUAN CT, Ma WL
    Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.
    Blood. 2024;143:2106.
    >> Share

  226. RIBERA JM
    MRD: also for T-lymphoblastic lymphoma.
    Blood. 2024;143:2017-2019.
    >> Share

  227. HILTON LK, Collinge BJ, Ben-Neriah S, Alduaij W, et al
    Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
    Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251.
    >> Share

  228. KIM J, Cho J, Lee MH, Yoon SE, et al
    Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
    Blood. 2024 May 2:blood.2023023419. doi: 10.1182/blood.2023023419.
    >> Share

  229. ARORA J, Ayyappan S, Yin C, Smith BJ, et al
    T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
    Blood. 2024;143:1816-1824.
    >> Share

    April 2024
  230. SARKOZY C, Callanan MB, Thieblemont C, Oberic L, et al
    Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
    Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.
    >> Share

  231. HANDUNNETTI SM, Anderson MA, Burbury KI, Thompson PA, et al
    Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
    Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388.
    >> Share

  232. CROCHET G, Iacoboni G, Couturier A, Bachy E, et al
    Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
    Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526.
    >> Share

  233. MAYBURY BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, et al
    Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.
    Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048.
    >> Share

  234. LOCKE FL, Siddiqi T, Jacobson CA, Ghobadi A, et al
    Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
    Blood. 2024 Apr 18:blood.2023023447. doi: 10.1182/blood.2023023447.
    >> Share

  235. SUREDA-GOMEZ M, Iaccarino I, De Bolos A, Meyer MA, et al
    SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features.
    Blood. 2024 Apr 15:blood.2023023242. doi: 10.1182/blood.2023023242.
    >> Share

  236. MERLIO JP
    Staphylococcus aureus and Sezary syndrome.
    Blood. 2024;143:1436-1438.
    >> Share

  237. WEI Q, Bueso-Ramos CE
    Thymoma with aberrant expression of CD20: a potential diagnostic pitfall of B-cell lymphoma.
    Blood. 2024;143:1551.
    >> Share

  238. VADIVEL CK, Willerslev-Olsen A, Namini MRJ, Zeng Z, et al
    Staphylococcus aureus induces drug resistance in cancer T cells in Sezary syndrome.
    Blood. 2024;143:1496-1512.
    >> Share

  239. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
    Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
    Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
    >> Share

  240. MARCAIS A
    Targeting PD-L1 to treat ATLL?
    Blood. 2024;143:1320-1322.
    >> Share

  241. LOCKE FL, Oluwole OO, Kuruvilla J, Thieblemont C, et al
    Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
    Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620.
    >> Share

    March 2024
  242. GROVER NS, Beaven AW
    T-cell lymphoma: the CAR-T revolution is coming.
    Blood. 2024;143:1201-1202.
    >> Share

  243. GIESSINGER J, Pullarkat ST
    An unusual presentation of lymphoplasmacytic lymphoma with isolated brachial plexus infiltration and amyloidosis.
    Blood. 2024;143:1315.
    >> Share


  244. Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.
    Blood. 2024;143:1316.
    >> Share

  245. HILL LC, Rouce RH, Wu MJ, Wang T, et al
    Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
    Blood. 2024;143:1231-1241.
    >> Share

  246. STEIDL C, Stevenson FK
    Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.
    Blood. 2024;143:1057-1058.
    >> Share

  247. RYAN CE, Armand P, LaCasce AS
    Frontline Treatment of Mantle Cell Lymphoma.
    Blood. 2024 Mar 18:blood.2023022352. doi: 10.1182/blood.2023022352.
    >> Share

  248. GODFREY JK, Gao L, Shouse G, Song JY, et al
    Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
    Blood. 2024 Mar 14:blood.2024024168. doi: 10.1182/blood.2024024168.
    >> Share

  249. MOLIN D
    Aging Kairos: treating older Hodgkin patients.
    Blood. 2024;143:943-945.
    >> Share

  250. EL HUSSEIN S
    Monomorphic epitheliotropic T-cell lymphoma with strong CD4 expression.
    Blood. 2024;143:1055.
    >> Share

  251. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
    MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
    Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
    >> Share

  252. AHMED R, Feldman AL
    Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
    Blood. 2024;143:938.
    >> Share

    February 2024
  253. SCHUSTER SJ, Huw LY, Bolen CR, Maximov V, et al
    Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
    Blood. 2024;143:822-832.
    >> Share

  254. FRIEDBERG JW, Bordoni R, Patel-Donnelly D, Larson T, et al
    Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
    Blood. 2024;143:786-795.
    >> Share

  255. OLSZEWSKI AJ
    When B cells rebuff bispecifics.
    Blood. 2024;143:744-746.
    >> Share

  256. LYNCH RC
    Toward a cure for cHL without chemotherapy.
    Blood. 2024;143:741-742.
    >> Share

  257. ANG Z, Thomas-Tikhonenko A
    Lymphoma immunotherapy: the garden of forking paths.
    Blood. 2024;143:655-657.
    >> Share

  258. SCHOOLCRAFT DK, Karrs JX
    Flower cell morphology in high-grade B-cell lymphoma of the maxillary sinus.
    Blood. 2024;143:738.
    >> Share

  259. BOARDMAN AP, Palomba ML
    Does BTKi improve CAR T-cell therapy in MCL?
    Blood. 2024;143:653-655.
    >> Share

  260. TONINO SH, Kersten MJ
    The quest for a cure in follicular lymphoma.
    Blood. 2024;143:475-476.
    >> Share

  261. WINTER JN, Ferreri AJM
    Predicting outcomes in CNS lymphoma with ctDNA.
    Blood. 2024;143:478-480.
    >> Share

  262. HEGER JM, Mattlener J, Schneider J, Godel P, et al
    Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
    Blood. 2024;143:522-534.
    >> Share

  263. CASULO C
    How do you define treatment success in MZL?
    Blood. 2024;143:382-383.
    >> Share

  264. DARNELL EP, Frigault MJ
    Two years later: CD19 CAR-T going the distance.
    Blood. 2024;143:379-380.
    >> Share

  265. GANDHI MK, Kelly GL
    EBNA2: a viral maestra conducting a symphony orchestra.
    Blood. 2024;143:384-385.
    >> Share

    January 2024
  266. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
    SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Blood. 2024 Jan 18:blood.2023022241. doi: 10.1182/blood.2023022241.
    >> Share

  267. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
    SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Blood. 2024;143:1953-1964.
    >> Share

  268. CERCHIETTI L
    Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B cell lymphoma.
    Blood. 2024 Jan 11:blood.2023021002. doi: 10.1182/blood.2023021002.
    >> Share

  269. COPPO P, Ricard L
    Plasmablastic lymphoma: better refine prognosis.
    Blood. 2024;143:101-102.
    >> Share

  270. DREYLING M, Fowler NH, Dickinson M, Martinez-Lopez J, et al
    Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
    Blood. 2024 Jan 9:blood.2023021567. doi: 10.1182/blood.2023021567.
    >> Share

  271. RADTKE A, Roschewski M
    The follicular lymphoma tumor microenvironment at single cell and spatial resolution.
    Blood. 2024 Jan 9:blood.2023020999. doi: 10.1182/blood.2023020999.
    >> Share

    December 2023
  272. BARRACLOUGH A, Hawkes EA
    Tribulations of trials in aggressive lymphoma.
    Blood. 2023;142:2232-2234.
    >> Share

  273. VEELKEN H
    Energy overpowers sweet tooth in FL.
    Blood. 2023;142:2226-2229.
    >> Share

  274. CHIBA M, Shimono J, Suto K, Ishio T, et al
    Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
    Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
    >> Share

  275. SHEA L, Mehta-Shah N
    Peripheral T-cell lymphoma: Are all patients high-risk?
    Blood. 2023 Dec 24:blood.2023020912. doi: 10.1182/blood.2023020912.
    >> Share

  276. FU L, Gong S
    KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
    Blood. 2023;142:2220.
    >> Share

  277. LAURENT C, Dietrich S, Tarte K
    Cell crosstalk within lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
    Blood. 2023 Dec 14:blood.2023021000. doi: 10.1182/blood.2023021000.
    >> Share

  278. SPAARGAREN M
    What's brewing for MALT1 in lymphoma?
    Blood. 2023;142:1939-1941.
    >> Share

  279. LUU BE, Xu SA
    A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma.
    Blood. 2023;142:2034.
    >> Share

  280. WIMBERGER N, Ober F, Avar G, Grau M, et al
    Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
    Blood. 2023;142:1985-2001.
    >> Share

    November 2023
  281. RAUERT-WUNDERLICH H
    EGR1 changes course in B-cell lymphoma.
    Blood. 2023;142:1850-1851.
    >> Share

  282. CAI J, Lee J
    Cold agglutinin syndrome with unexpected bone marrow CD5+ diffuse large B-cell lymphoma.
    Blood. 2023;142:1935.
    >> Share

  283. ALDERUCCIO JP, Nayak L, Cwynarski K
    How I treat secondary CNS involvement by aggressive lymphomas.
    Blood. 2023;142:1771-1783.
    >> Share

  284. STEVENSON FK PROFESSOR, Forconi F
    The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells.
    Blood. 2023 Nov 22:blood.2023022703. doi: 10.1182/blood.2023022703.
    >> Share

  285. GHESQUIERES H, Krzisch D, Nicolas Virelizier E, Kanoun S, et al
    Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
    Blood. 2023 Nov 18:blood.2023021564. doi: 10.1182/blood.2023021564.
    >> Share

  286. DUELL J, Leipold AM, Appenzeller S, Fuhr V, et al
    Sequential Antigen-loss and Branching Evolution in Lymphoma after CD19- and CD20-Targeted T-cell Redirecting Therapy.
    Blood. 2023 Nov 17:blood.2023021672. doi: 10.1182/blood.2023021672.
    >> Share

  287. MURAKAMI MA
    Toward rational therapy for mantle cell lymphoma.
    Blood. 2023;142:1504-1506.
    >> Share

  288. ETANCELIN P, Boussaid I
    Two sides of the same coin: transdifferentiation from Burkitt lymphoma to histiocytic sarcoma.
    Blood. 2023;142:1576.
    >> Share

    October 2023
  289. ABRAMSON JS, Palomba ML, Gordon LI, Lunning MA, et al
    Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
    Blood. 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854.
    >> Share

  290. MINSON AG, Hamad N, Cheah CY, Tam CS, et al
    CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.
    Blood. 2023 Oct 26:blood.2023021306. doi: 10.1182/blood.2023021306.
    >> Share

  291. BROCKELMANN PJ
    AXL-erating mantle cell lymphoma treatment.
    Blood. 2023;142:1411-1412.
    >> Share

  292. GINI G, Tani M, Tucci A, Marcheselli L, et al
    Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
    Blood. 2023;142:1438-1447.
    >> Share

  293. NEELAPU SS, Chavez JC, Sehgal A, Epperla N, et al
    Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5).
    Blood. 2023 Oct 25:blood.2023021243. doi: 10.1182/blood.2023021243.
    >> Share

  294. COLLINS GP
    Tackling PD1i resistance in Hodgkin lymphoma.
    Blood. 2023;142:1333-1334.
    >> Share

  295. BELADA D, Kopeckova K, Bergua Burgues JM, Stevens D, et al
    Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
    Blood. 2023;142:1348-1358.
    >> Share

  296. LEOPIZZI M, Mundo L, Messina E, Campolo F, et al
    Epstein-Barr virus encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Blood. 2023 Oct 17:blood.2023021346. doi: 10.1182/blood.2023021346.
    >> Share

  297. DI CIACCIO PR, Polizzotto MN, Cwynarski K, Gerrie AS, et al
    The Influence of Immunodeficiency, Disease Features and Patient Characteristics on Survival in Plasmablastic Lymphoma.
    Blood. 2023 Oct 13:blood.2023021348. doi: 10.1182/blood.2023021348.
    >> Share

  298. BOMMIER C, Zucca E, Chevret S, Conconi A, et al
    Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy.
    Blood. 2023 Oct 6:blood.2023020984. doi: 10.1182/blood.2023020984.
    >> Share

  299. RUSSLER-GERMAIN DA, Cliff ERS, Bartlett NL
    Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis.
    Blood. 2023 Oct 5:blood.2023022048. doi: 10.1182/blood.2023022048.
    >> Share


  300. Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491-503.
    Blood. 2023;142:1255.
    >> Share

  301. MANDATO E, Yan Q, Ouyang J, Paczkowska J, et al
    MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
    Blood. 2023;142:1219-1232.
    >> Share

    September 2023

  302. Balsas P, Veloza L, Clot G, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202-2215.
    Blood. 2023;142:1173-1176.
    >> Share

  303. NARITA K, Takeuchi K
    FISH for EBV genome in a patient with diffuse large B-cell lymphoma harboring t(14;18)(q32;q21).
    Blood. 2023;142:1172.
    >> Share

  304. ZHOU N, Busino L
    Targeting epigenetics and ferroptosis in DLBCL.
    Blood. 2023;142:1108-1109.
    >> Share

  305. DIEPSTRA A, Nolte IM, van den Berg A, Magpantay LI, et al
    Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years.
    Blood. 2023 Sep 25:blood.2023020959. doi: 10.1182/blood.2023020959.
    >> Share

  306. LIU Y, Kimpara S, Hoang NM, Daenthanasanmak A, et al
    EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.
    Blood. 2023 Sep 22:blood.2023020142. doi: 10.1182/blood.2023020142.
    >> Share

  307. QUALLS DA, Lambert N, Caimi PF, Merrill MH, et al
    Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study.
    Blood. 2023 Sep 22:blood.2023021274. doi: 10.1182/blood.2023021274.
    >> Share

  308. FREEMAN CL, Locke FL
    CARs put age in the rearview mirror.
    Blood. 2023;142:1029-1031.
    >> Share


  309. Williams AM, Salehabadi SM, Xing M, et al. Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma. Blood. 2022;139(20):3073-3086.
    Blood. 2023;142:1028.
    >> Share

  310. ZHOU N, Choi J, Grothusen G, Kim BJ, et al
    DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
    Blood. 2023;142:973-988.
    >> Share

  311. HAEBE SE, Day G, Czerwinski DK, Sathe A, et al
    Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.
    Blood. 2023 Sep 8:blood.2023020360. doi: 10.1182/blood.2023020360.
    >> Share

  312. CHEAH CY
    Pembrolizumab: a key for some, but not all, HL.
    Blood. 2023;142:861-862.
    >> Share


  313. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
    Blood. 2023;142:940.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016